Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.
about
Fabry disease: recent advances in pathology, diagnosis, treatment and monitoringSafety and efficacy of enzyme replacement therapy in the nephropathy of Fabry diseaseLysosomal storage diseases and the heat shock response: convergences and therapeutic opportunitiesMannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cellsCardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry diseaseInduced pluripotent stem cells derived from mouse models of lysosomal storage disordersFabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina.Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's diseaseCommon and uncommon pathogenic cascades in lysosomal storage diseasesGenetic screening of Fabry patients with EcoTILLING and HRM technology.Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.Cerebral hemodynamics and endothelial function in patients with Fabry diseaseSex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.Innate and Adaptive Immune Response in Fabry DiseaseEvaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patientsUric Acid as a Marker of Mortality and Morbidity in Fabry Disease.Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells.Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptorReduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry DiseaseInvolvement of ROS in BBB dysfunction.Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE-/- mice.Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?Fabry's disease: an example of cardiorenal syndrome type 5.Altered Met Receptor Phosphorylation and LRP1 Mediated Uptake in Cells Lacking Carbohydrate-Dependent Lysosomal Targeting.Globotriaosylsphingosine induces oxidative DNA damage in cultured kidney cells.Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.HIV Tat Domain Improves Cross-correction of Human Galactocerebrosidase in a Gene- and Flanking Sequence-dependent Manner.Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease.Integrative Systems Biology Investigation of Fabry Disease.Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.Pathomechanisms of renal Fabry disease.Fabry disease and Factor V Leiden: a potent vascular risk combination.
P2860
Q21202889-0EAAF6C4-15AE-4992-ADD6-B1D09193BAD3Q24650910-22BB17BC-CF28-4A22-A4B2-7903EDDACB2DQ27004531-B27EDD4F-48D0-46F4-8013-C60B285E7650Q28727768-EBAA1A93-3771-4B15-B5BC-1EDD4CCDD06EQ28730130-8FECA5E2-CCD9-4812-80F0-DC2D237C228CQ30494447-6E1919E1-3915-4831-8607-6778E54BA824Q33645550-C7576D7D-16A1-4D2E-AFF8-CBA6B68BBC8BQ33726258-57A36923-A36B-4D17-9F36-9E24D5223F51Q33831482-FA15B5F6-5AC8-43AF-91BC-C57E2A763EC3Q33937755-06110A5F-66E0-4024-9940-DBAC4E4E6D72Q33966917-725D091D-6489-4C90-B3BD-52508FB287DDQ34012395-C8482D34-D8EF-45E9-AD57-0997F21EE02AQ34257466-DA0EC445-C114-4261-89EA-4978E158B58CQ34577897-0693CC57-BAD9-4085-AB6E-8B8E99619CE5Q35037435-C2D3AA5F-7A66-4F45-B2DF-FDFC81834167Q35152240-D8A1343A-5F04-442A-A035-C80FA6FD3C67Q35800976-D8553BF7-6786-490D-9B0E-7622DC9FEBE3Q36075584-42EB6988-CFFE-46CD-ACE2-4D6D5964F60CQ36189989-72F14EBF-58E5-4F52-85A3-45594083BFFAQ36219290-B06359FF-A0C5-4295-AC50-DF414CFF1760Q36475780-AE9489C0-2E6E-4EB5-8004-1E931C86D3FDQ36565901-A13425F0-1421-4CA6-92A8-4609E379A381Q37329223-7D854C3E-F677-4217-B1B9-007850977A3CQ37400756-70701428-19F0-464A-A969-B3920E368783Q37698833-E8ABC0F9-34A4-4851-9BDB-A82C9DF3E9BFQ38152826-0165B9F5-F828-46D2-AD6F-052C1B645663Q38558725-777480E8-F7C5-4694-B69F-D67B8884C539Q38671502-679967F1-38C1-41F8-8DFA-6A0B82704CB0Q38827299-924C811B-A3A1-494C-8498-D2E770C9D77AQ38844401-789C78A0-AB00-4BAF-8ED1-521B8EBDB26FQ39636269-16A94196-4883-42C1-A9FC-4696D4A26104Q39776866-EA67F3E9-559C-4D43-B46B-80DE4692ECA0Q40351353-5C53A21C-C959-4D9F-B1BC-5DCE45B216FCQ41689988-C687A039-6757-4AC0-94F7-9E41C3DA1C99Q42110868-DA4EA2F2-056D-4794-9982-BFFB58A58B01Q42599584-A2185FCE-2271-4339-ABBB-38BD24D17E85Q47094778-0D84083B-6763-45F2-9965-B14471C0424AQ47123134-8256F968-CD93-4257-9AB2-6769AD52F1EBQ48287690-581E3DD9-B408-44B1-86E2-4F4BAC1D506EQ48664517-F0DF35E3-570A-4654-A130-B17AD85E967B
P2860
Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Globotriaosylceramide induces ...... bry disease endothelial cells.
@en
type
label
Globotriaosylceramide induces ...... bry disease endothelial cells.
@en
prefLabel
Globotriaosylceramide induces ...... bry disease endothelial cells.
@en
P2093
P2860
P1476
Globotriaosylceramide induces ...... abry disease endothelial cells
@en
P2093
David F Moore
James A Shayman
Jane M Quirk
Jin-Song Shen
Raphael Schiffmann
Xing-Li Meng
P2860
P304
P356
10.1016/J.YMGME.2008.06.016
P577
2008-08-15T00:00:00Z